Literature DB >> 15053235

Membrane-type matrix metalloproteinase-1 (MT1-MMP) is down-regulated in estrogen-deficient rat osteoblast in vivo.

E Y Liao1, H J Liao, L J Guo, H D Zhou, X P Wu, R C Dai, X H Luo.   

Abstract

Our previous study showed that estrogen stimulates membrane-type matrix metalloproteinases-1 (MT1-MMP) production in osteoblastic cells culture, but has no effect on MMP-2 and TIMP-2 synthesis. Osteoblast-derived MT1-MMP have been recently implied to play a role in bone metabolism by degrading tumor necrosis factor-alpha (TNF-alpha), resolving extracellular matrix and activating proMMP-2, which requires the process of activation mediated by MT1-MMP/tissue inhibitor of metalloproteinase (TIMP-2) complex on the cell surface. To investigate the mechanism of bone loss following estrogen deficiency, we examined the effects of estrogen on osteoblast synthesis of MT1-MMP, MMP-2 and TIMP-2. In situ hybridization and immunohistochemistry of rat bone samples were used to document the synthesis of MT1-MMP, MMP-2, and TIMP-2 mRNA and protein. Osteoblasts from distal femoral head showed an increase in the pattern of MT1-MMP mRNA and protein production in sham-operated controls and 17beta-estradiol (E2)-treated rats, compared with the ovariectomized group; the synthesis of MMP-2 and TIMP-2 mRNA and protein was unaffected. Our data show a down-regulation of MT1-MMP synthesis by osteoblast in vivo following estrogen withdrawal, and treatment with E2 resulted in induced MT1-MMP expression in vivo. There is evidence suggesting a role for MT1-MMP in the process of bone loss during the pathogenesis of osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15053235     DOI: 10.1007/bf03350902

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  21 in total

1.  The C-terminal domain of tissue inhibitor of metalloproteinases-2 is required for cell binding but not for antimetalloproteinase activity.

Authors:  Y C Ko; K E Langley; E A Mendiaz; V P Parker; S M Taylor; Y A DeClerck
Journal:  Biochem Biophys Res Commun       Date:  1997-07-09       Impact factor: 3.575

Review 2.  Regulation of matrix metalloproteinase expression in tumor invasion.

Authors:  J Westermarck; V M Kähäri
Journal:  FASEB J       Date:  1999-05       Impact factor: 5.191

3.  TIMP-2 is required for efficient activation of proMMP-2 in vivo.

Authors:  Z Wang; R Juttermann; P D Soloway
Journal:  J Biol Chem       Date:  2000-08-25       Impact factor: 5.157

4.  Cell surface binding of TIMP-2 and pro-MMP-2/TIMP-2 complex.

Authors:  M R Emmert-Buck; H P Emonard; M L Corcoran; H C Krutzsch; J M Foidart; W G Stetler-Stevenson
Journal:  FEBS Lett       Date:  1995-05-01       Impact factor: 4.124

Review 5.  Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis.

Authors:  S C Manolagas; R L Jilka
Journal:  N Engl J Med       Date:  1995-02-02       Impact factor: 91.245

Review 6.  Skeletal effects of estrogen.

Authors:  R T Turner; B L Riggs; T C Spelsberg
Journal:  Endocr Rev       Date:  1994-06       Impact factor: 19.871

7.  Processing of tumour necrosis factor-alpha precursor by metalloproteinases.

Authors:  A J Gearing; P Beckett; M Christodoulou; M Churchill; J Clements; A H Davidson; A H Drummond; W A Galloway; R Gilbert; J L Gordon
Journal:  Nature       Date:  1994-08-18       Impact factor: 49.962

8.  Membrane-type matrix metalloproteinase 1 is a gelatinolytic enzyme and is secreted in a complex with tissue inhibitor of metalloproteinases 2.

Authors:  K Imai; E Ohuchi; T Aoki; H Nomura; Y Fujii; H Sato; M Seiki; Y Okada
Journal:  Cancer Res       Date:  1996-06-15       Impact factor: 12.701

9.  A matrix metalloproteinase expressed on the surface of invasive tumour cells.

Authors:  H Sato; T Takino; Y Okada; J Cao; A Shinagawa; E Yamamoto; M Seiki
Journal:  Nature       Date:  1994-07-07       Impact factor: 49.962

10.  MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover.

Authors:  K Holmbeck; P Bianco; J Caterina; S Yamada; M Kromer; S A Kuznetsov; M Mankani; P G Robey; A R Poole; I Pidoux; J M Ward; H Birkedal-Hansen
Journal:  Cell       Date:  1999-10-01       Impact factor: 41.582

View more
  2 in total

1.  MT1-MMP-dependent control of skeletal stem cell commitment via a β1-integrin/YAP/TAZ signaling axis.

Authors:  Yi Tang; R Grant Rowe; Elliot L Botvinick; Abhishek Kurup; Andrew J Putnam; Motoharu Seiki; Valerie M Weaver; Evan T Keller; Steven Goldstein; Jinlu Dai; Dana Begun; Thomas Saunders; Stephen J Weiss
Journal:  Dev Cell       Date:  2013-05-16       Impact factor: 12.270

2.  Subtype specific estrogen receptor action protects against changes in MMP-2 activation in mouse retinal pigmented epithelial cells.

Authors:  Sharon Elliot; Paola Catanuto; Pedro Fernandez; Diego Espinosa-Heidmann; Michael Karl; Kenneth Korach; Scott W Cousins
Journal:  Exp Eye Res       Date:  2008-01-17       Impact factor: 3.467

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.